Puma Biotechnology's NERLYNX Added To NCCN Guidelines For HER2-Mutated Cervical Cancer; Approved As Second-Line Therapy For Recurrent Or Metastatic Disease Based On Phase II SUMMIT Trial Results
Puma Biotechnology's NERLYNX Added To NCCN Guidelines For HER2-Mutated Cervical Cancer; Approved As Second-Line Therapy For Recurrent Or Metastatic Disease Based On Phase II SUMMIT Trial Results
Puma Biotechnology的NERLYNX被纳入NCCN指南，用于HER2突变的宫颈癌；根据II期SUMMIt试验结果，获批作为复发或转移性疾病的二线治疗。
Puma Biotechnology's NERLYNX Added To NCCN Guidelines For HER2-Mutated Cervical Cancer; Approved As Second-Line Therapy For Recurrent Or Metastatic Disease Based On Phase II SUMMIT Trial Results
Puma Biotechnology 的 NERLYNX 已加入 NCCN HER2 突变宫颈癌指南；根据二期 SumMit 试验结果，批准为复发性或转移性疾病的二线疗法
资讯热榜
更新时间